Company Overview and News

 
New residential, tourism funds planned in Auckland and Queenstown by Augusta Capital

2018-03-27 nzherald.co.nz
An NZX-listed property specialist, which manages assets worth about $1.7 billion, is planning new residential and tourism investment funds in Auckland and Queenstown, with assets of $300m to $400m in each entity.

 
Shares keep falling amid global sell-off

2018-03-26 nzherald.co.nz
New Zealand's S&P/NZX 50 Index fell about 1 per cent for the second straight session, joining a global selloff that started on Wall Street and extended into Asia amid fears of a trade war. Spark NZ, Air New Zealand, Sky Network Television and A2 Milk all fell.

 
MARKET CLOSE: NZ shares join global sell-off

2018-03-26 nbr.co.nz
(BusinessDesk) - New Zealand's S&P/NZX 50 Index fell about 1 percent for the second straight session, joining a global selloff that started on Wall Street and extended into Asia amid fears of a trade war. Spark NZ, Air New Zealand, Sky Network Television and A2 Milk all fell.

 
New Zealand shares rise as Sky TV bounce continues

2018-03-19 nzherald.co.nz
New Zealand shares were mixed, with Kathmandu Holdings up and Sky Network Television continuing to bounce while Chorus and Comvita fell.

 
MARKET CLOSE: NZ shares mixed

2018-03-19 nbr.co.nz
(BusinessDesk) - New Zealand shares were mixed, with Kathmandu Holdings up and Sky Network Television continuing to bounce while Chorus and Comvita fell.

 
Mansons' $1b-plus Auckland order book

2018-03-02 nzherald.co.nz
New Zealand's largest private developers, Mansons TCLM, has $1 billion-plus of work on and just completed.

 
NZ shares fall, capping 3.7% weekly decline

2018-02-09 nzherald.co.nz
New Zealand shares fell, rounding out a 3.7 per cent weekly decline as investors adjust to increased volatility and rising global bond yields that are undermining equity markets that have been at record highs. SkyCity Entertainment Group gained after kicking off earnings season and Scales Corp fell.

 
NZ shares jump 1.7% on heavier turnover as Xero leaves NZX

2018-01-31 nzherald.co.nz
New Zealand shares rose on a busier day than usual, marking the final day of trading for one-time market darling Xero.

 
Ryman Healthcare and A2 Milk lead sharemarket higher

2018-01-22 nzherald.co.nz
New Zealand shares gained, led higher by Ryman Healthcare and A2 Milk Co on some positioning ahead of upcoming earnings, while Infratil and Fonterra Shareholders Fund dropped.

1
Sharemarket slips in thin holiday trade

2017-12-27 nzherald.co.nz
New Zealand shares slipped in thin holiday trading as appetite declined for companies offering attractive dividend yields, such as regulated utilities Chorus and Genesis Energy and pay-TV operator Sky Network Television.

1
Augusta buys second property for industrial fund

2017-12-26 nzherald.co.nz
Augusta Capital has bought a second property which it plans to add to an industrial property fund scheduled to launch next year.

 
Sharemarket rises with investors in buoyant mood

2017-12-11 nzherald.co.nz
New Zealand shares rose, led by Metro Performance Glass and Heartland Bank, while dairy-related companies a2 Milk Co and Synlait Milk continued to weaken.

 
Augusta Capital buys Wellington industrial property

2017-12-10 nzherald.co.nz
Augusta Capital has unconditionally purchased a Wellington industrial property as a seed asset for a new industrial fund that is expected to initially raise between $50 million and $70m of equity when it launches early next year.

 
Augusta first-half profit halves on revaluations

2017-11-12 nzherald.co.nz
Augusta Capital's first-half profit more than halved as the company wrote down the value of its stake in listed property investor NPT and didn't repeat year-earlier valuation gains as the firm continues its shift into funds management rather than direct property ownership.

 
NPT sells its interest in Auckland high-rise to SkyCity for $47 million

2017-10-12 nzherald.co.nz
NPT, the listed property investor, has sold its interest in the AA Centre in central Auckland to SkyCity Entertainment Group for $47 million, as it looks to reposition the business after a board overhaul.

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...